Discussion
We conduct a phase II study to investigate the safety and efficacy of durvalumab combined with anlotinib as maintenance treatment in ES‐SCLC patients.
Bo Zhang and Chunlei Shi contributed equally to this work.Trial registration: NCT04985851 (date of registration: 2 August 2021).